All work and no play

Article

The ESCRS will be organizing a number of sightseeing tours during the meeting. The London City Tour will take in the major sights of London, including Buckingham Palace, Westminster Abbey, Harrods, Trafalgar Square, St Paul's Cathedral and much more. There will also be an opportunity to visit Windsor Castle and Hampton Court Palace, home to the British monarchy past and present.

All work and no play?

If you prefer getting out on your own, OTE would like to recommend a number of sites that are well worth a visit:

The London Eye was constructed to celebrate the millennium and has fast become an essential part of the city's experience as well as being a dramatic feature of London's skyline. At 140 m tall, it is the sixth largest structure in the city and, from this height, and with the benefit of 360° views, there can be no better way to see London.

The £25 million London Aquarium is one of Europe's largest exhibitions of global aquatic life, displayed in over 2 million litres of water. The Aquarium combines education, relaxation and entertainment through a multi-sensory voyage of discovery through the rivers, lakes and oceans of the world. There is nowhere else in the capital where visitors can come face-to-face with sharks, watch piranhas at feeding time and stroke friendly rays.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.